PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 61.5441

Change

+0.46 (+0.76)%

Market Cap

N/A

Volume

4.34K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-28 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.55 (+0.40%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.24 (+0.37%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+0.33 (+0.33%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+0.03 (+0.04%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.34 (+1.67%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

+0.46 (+0.48%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.47 (+1.65%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.04 (-0.15%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.70 (+1.23%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.24 (+1.28%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.49% 29% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.49% 29% F 30% F
Trailing 12 Months  
Capital Gain 0.18% 62% D 46% F
Dividend Return 0.01% 6% D- N/A F
Total Return 0.19% 62% D 36% F
Trailing 5 Years  
Capital Gain 13.62% 43% F 42% F
Dividend Return 0.08% 5% F N/A F
Total Return 13.71% 43% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 2.32% 48% F 45% F
Dividend Return 2.33% 48% F 35% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 16.70% 57% F 60% D-
Risk Adjusted Return 13.96% 52% F 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.